Loading, Please Wait...
WALTHAM, Mass., April 10, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced multiple data presentations on ETX2514SUL and ETX0282CPDP as well as its preclinical non-beta-lactam PBP inhibitor (NBP) program at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), taking place April 13-16, 2019 in Amsterdam, Netherlands.
In addition to two oral presentations and five poster presentations on the scientific program, Entasis Chief Executive Officer Manos Perros, PhD will present in an invitation-only industry panel discussion, “Therapeutics Pipeline Corner,” to discuss Entasis’ unique research and development strategies and updates on its portfolio of precision antibiotics.
"Results from these studies further demonstrate the potent antibacterial activity of our pipeline candidates against specific pathogens and further support the recent initiation of our ATTACK Phase 3 global pivotal trial of ETX2514SUL in patients with Acinetobacter baumannii infections and the continued development of ETX0282CPDP for the treatment of antibiotic-resistant Enterobacteriaceae urinary tract infections,” said Manos Perros, Chief Executive Officer, Entasis Therapeutics. “We look forward to discussing these new datasets and innovative strategies to combat the critical global issue of antibiotic resistance with the infectious diseases community at ECCMID 2019.”
Mini-Oral #300: A double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of intravenous sulbactam-ETX2514 in the treatment of hospitalized adults with complicated urinary tract infections, including acute pyelonephritis
Panel Presentation: Therapeutics Pipeline Corner
Oral Presentation #527: Discovery of a novel series of penicillin-binding protein 3 inhibitors as monotherapy for Pseudomonas aeruginosa infections: rational design of biochemical potency and bacterial permeation
ETX2514 Poster Presentations:
Poster #P1185: The novel beta-lactamase inhibitor ETX2514 effectively restores sulbactam activity against recent global Acinetobacter baumanniicalcoaceticus complex clinical isolates
Poster #P1186: The susceptibility of global isolates of Acinetobacter baumannii to ETX2514SUL and comparators
Poster #P1953: Population Pharmacokinetic (PPK) and Pharmacokinetic-Pharmacodynamic (PKPD) Target Attainment (TA) Analyses of ETX2514SUL to Support Dosing Regimens in Patients with Varying Renal Function
ETX0282 (ETX1317) Poster Presentations
Poster #P1184: The novel beta-lactamase inhibitor ETX1317 effectively restores the activity of cefpodoxime against recent global Enterobacteriaceae isolates from urinary tract infections
Poster #P1991: Efficacy of Cefpodoxime proxetil and ETX0282 in a murine UTI model with E. coli and K. pneumoniae
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Both ETX0282CPDP and NBP are powered by CARB-X. For more information, visit www.entasistx.com.
Entasis Company Contact
Investor Relations Contact
The Ruth Group
The Ruth Group